Endocrine Abstracts

Objective: Prospective study of medical treatment effect in newly diagnosed patients with large and giant prolactinomas.Patients and methods: The study group included 45 patients with large prolactinomas (tumors more 3,6 cm) and 23 patients with giant prolactinomas (tumors more than 6 cm); from them 8 mainly cystic tumors. The treatment period was 3–24 month (mean 6). Serum prolactin level before treatment ranged between 12 990 and 1 038 000 mU/l (m...

Thyrotropinoma (TSH-secreting pituitary adenomas, TSH-AG) are rare tumor of the pituitary (0.5–2% of all pituitary adenomas). Localization of the tumor with the appropriate neuroendocrine disorders has features in the clinic. This is due to the direct damage to the nucleus and structures of the pituitary with hypersecretion of TSH, which leads to overstimulation of the thyroid gland and the emergence of the clinical picture of ‘central’ hyperthyroidism. Differen...

A 32-year-old woman presented with primary amenorrhea, prolactin (PRL) level of 154150 mIU/l (40–530 mIU/l) diagnosed with an endo-supra-infra-laterosellar giant pituitary adenoma measuring maximum 6.2 cm. The patient was prescribed a treatment with cabergoline (CAB) at an initial dose of 0.5 mg per week. The treatment decreased the tumour size and brought to normal the level of PRL. After 7 months of CAB treatment menarche was achieved, after 12 months the patient became...

Objective: Prospective study of cabergoline effect in newly diagnosed patients with giant invasive prolactinomas.Patients and methods: The study group included 121 patients with giant prolactinomas (tumors larger than 40 mm in size); among them 49 patients had tumors larger than 60 mm in size. 91 male and 30 female aged 16–67 years (median 37) were treated with 0.5–3.5 mg/week (mean 1.5 mg) cabergoline. The treatment period was 6–120 month...

Objective: To study the clinical, diagnostic and morphological characteristics and treatment outcomes of TSH-secreting pituitary tumors.Patients and methods: The study included 21 patients with pituitary adenoma and a normal or elevated TSH level and elevated fT4 and fT3 levels who were operated on at the Neurosurgical Institute in the period between 2002 and 2015. Before surgery, in the early postoperative period, and 6 months afte...

Introduction: Craniopharyngiomas (CF)- benign epithelial tumors that develop from the remnants of Rathke’s pouch cells. Most often, CF manifest themselves in two age groups: in children 5–14 years old making 5.6–13% of intracranial tumors and in adults 50–74 years old making 2–5%.Materials and methods: In the last decade, the Institute annually for the surgical treatment received 100–120 patients with CF. The total number of...

The tumors of the thalamic-hypothalamic-pituitary system (diencephalon region, DR) include a fairly large group. These are pituitary adenomas, craniopharyngiomas (CP), pineal tumors, gliomas, meningiomas, and others. Tumors differ in the location, histological structure, and manifestations of the clinical picture with the corresponding hormonal changes, approaches and methods in treatment. Psychopathological symptoms are revealed in the symptoms of lesion of the DR in addition...